Here are three things to know:
1. Zealand Pharma has a proprietary peptide technology. UQ’s Institute for Molecular Bioscience’s has a large collection of animal venoms, and IMB researchers have extensive experience in identifying novel bioactive peptides from venoms.
2. Zealand and the university researchers will work together to identify venom-derived peptides that act against a range of drug targets to treat gastrointestinal and metabolic diseases. Zealand will then further develop these novel drug candidates.
3. UQ is ranked in the top 20 universities for life sciences research in the world. The collaboration will also draw on expertise from Flinders University in South Australia.
More articles on gastroenterology:
GI leader to know: Dr. Atul Vachhani of Santa Maria Gastroenterology
Dr. Khalid Naseer joins Crossroads Specialty Clinic — 3 insights
Want to improve outcomes and save money? Implement an enhanced recovery protocol
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.